Compass Therapeutics shed half its stock price this morning as investors digested its bispecific antibody’s failure to hit an overall survival (OS) endpoint in a phase 2/3 study. The Boston-based ...

A newfound nocturnal navigation system challenges what entomologists thought they knew about how ants find their way ...

Compass Therapeutics said its cancer treatment improved progression-free survival in a recent trial, but didn't meet its secondary endpoint in overall survival. Shares sank 61% to $1.96, at one point ...

Compass Therapeutics said its cancer treatment improved progression-free survival in a recent trial, but didn't meet its secondary endpoint in overall survival. Shares fell 23% to $3.85 in premarket ...

You can spend many hours gathering common resources and progressing through the game without thinking about it.

Are you wondering about how to heal your character in Subnautica 2? The world of Proteus is full of mysteries and wonders, ...

Join us as we unbox and review a compact Zombie Survival Essential Survival Kit packed with gear for any emergency. From a ...

If the latest Netflix release, "Apex," gave you chills, here are some of the best survival thrillers on the streaming service ...

As recently announced, tovecimig (DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel demonstrated a highly statistically significant improvement in progression-free survival (PFS) versu ...

Compass Therapeutics Inc. CMPX shares are tumbling on Monday as the company announced results from its COMPANION-002 study, which evaluated its drug tovecimig in patients with advanced biliary tract ...